Myriad Genetics Case

TitleMyriad Genetics Case
Publication TypeCase Study
Year of Publication2014
AuthorsBabbitt, S
Corporate AuthorsLoyola University Chicago,
Date Published04/2014
PublisherLoyola University Chicago
KeywordsBIOETHICS , business , GENETICS , Intellectual , Intellectual Property and Patents , MEDICINE
AbstractMyriad Genetics' patents on human genes have led to intense controversy and several lengthy court battles. Some of these patents, specifically of the genes (BRCA1 and BRCA2) responsible for predicting susceptibility to certain breast and ovarian cancers, were invalidated by the Supreme Court as a result of a suit filed by the ACLU and the Public Patent Foundation (PUBPAT). The suit was filed on the grounds that genes, as products of nature, cannot be patented and because of the excessive limitations such patents create for crucial biomedical procedures and research worldwide.
NotesCase from the National Undergraduate Bioethics Conference Bioethics Bowl. April 5, 2014. Loyola University, Chicago.
Full Text